Aspira Pathlab & Diagnostics has received an approval for the allotment of 30,00,000 equity Shares of Rs 10 each for cash at a price of Rs 17 per share (including a premium of Rs 7 per share), the price has been calculated in accordance with the SEBI (ICDR) Regulations, 2009, aggregating to Rs 5,10,00,000 on preferential basis to Promoters/ Promoter Groups and Strategic Investors not forming part of Promoters Group of the company. The Operation committee of Directors of the company at its meeting held on August 24, 2018, approved the same.
The Board has also given approval for the allotment of 55,00,000 9% Non-Convertible, Non-Cumulative, Non- Participating, Redeemable Preference Shares (NCRPS) of the face value of Rs 10 each on private placement basis to Yashraj Biotechnology, Promoter of the company for conversion of loan. The said preference shares are not proposed to listed on any stock exchange.
